Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids

July 23, 2025

U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review

July 14, 2025

From Bayer

Via Business Wire

BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases

July 08, 2025

From Bayer

Via Business Wire

Bayer Appoints Priyal Patel as Chief Financial Officer for North America

July 01, 2025

From Bayer

Via Business Wire

U.S. Supreme Court Asks for Views of Solicitor General in Durnell Case

June 30, 2025

From Bayer

Via Business Wire

Bayer Files for Approval of gadoquatrane in the U.S.

June 17, 2025

From Bayer

Via Business Wire

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

June 11, 2025

From Bayer

Via Business Wire

U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer

June 03, 2025

From Bayer

Via Business Wire

Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress

June 03, 2025

From Bayer

Via Business Wire

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated With Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study

June 02, 2025

From Bayer

Via Business Wire

CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

May 30, 2025

From Bayer

Via Business Wire

U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer

May 28, 2025

From Bayer

Via Business Wire

ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

May 28, 2025

From Bayer

Via Business Wire

ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT

May 27, 2025

From Bayer

Via Business Wire

Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

May 22, 2025

From Bayer

Via Business Wire

Bayer Highlights New Data from Oncology and Women’s Health Portfolios at 2025 ASCO Annual Meeting

May 21, 2025

From Bayer

Via Business Wire

U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor VIII Deficiency)

May 19, 2025

From Bayer

Via Business Wire

Passage of New Georgia Bill a Win for Farmers

May 12, 2025

From Bayer

Via Business Wire

Bayer U.S. Surveys Shed Further Light on the Diversity of Menopause Care Approaches and Menopause Symptom Experiences

May 08, 2025

From Bayer

Via Business Wire

Don’t Let Corn Rootworm Steal Your Yield: Bayer Launches The Watch 2025

May 05, 2025

From Bayer

Via Business Wire

AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)

April 29, 2025

From Bayer

Via Business Wire

Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma

April 29, 2025

From Bayer

Via Business Wire

Guru Ramamurthy Appointed as New CFO for Bayer’s Crop Science Division

April 29, 2025

From Bayer

Via Business Wire

Agricultural Community Applauds Signing of New North Dakota Bill

April 24, 2025

From Bayer

Via Business Wire

Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community

April 16, 2025

From Bayer

Via Business Wire

Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting

April 16, 2025

From Bayer

Via Business Wire

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors

April 10, 2025

From Bayer

Via Business Wire

Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case

April 04, 2025

From Bayer

Via Business Wire

Comprehensive Review of More Than 400 Studies Conducted Over 30 Years:

March 25, 2025

From Bayer

Via Business Wire

ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes

March 25, 2025

From Bayer

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.